Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

From the 12th to the 15th, the JP Morgan Healthcare Conference, widely regarded as the world’s largest pharmaceutical and ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

The dependency on Asia grows to supply its pharmaceutical industry and ensure the provision of essential medicines. Among the ...

AbbVie on Wednesday denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Pharma stocks are back in focus as obesity drugs, HIV prevention and biotech deal activity shape the outlook heading into ...

The United Kingdom's stock market has been experiencing fluctuations, with the FTSE 100 index recently closing lower due to weak trade data from China, highlighting ongoing global economic challenges.

Amgen is getting down with Disco Pharmaceuticals, commissioning the German biotech to work on cancer therapies focused on a ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...